Genor Biopharma Holdings (HKSE:06998) EPS (Basic) : HK$-0.11 (TTM As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Genor Biopharma Holdings EPS (Basic)?

Genor Biopharma Holdings's basic earnings per share (Basic EPS) for the six months ended in Dec. 2024 was HK$0.16. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2024 was HK$-0.11.

Genor Biopharma Holdings's EPS (Diluted) for the six months ended in Dec. 2024 was HK$0.16. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was HK$-0.11.

Genor Biopharma Holdings's EPS without NRI for the six months ended in Dec. 2024 was HK$0.16. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2024 was -0.11.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Genor Biopharma Holdings EPS (Basic) Historical Data

The historical data trend for Genor Biopharma Holdings's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genor Biopharma Holdings EPS (Basic) Chart

Genor Biopharma Holdings Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EPS (Basic)

Get a 7-Day Free Trial

-14.65

-2.14

-1.62

-1.46

-0.11

Genor Biopharma Holdings Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
EPS (Basic)	Get a 7-Day Free Trial							-0.72	-0.59	-0.86	-0.27	0.16

Genor Biopharma Holdings EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Genor Biopharma Holdings's Basic EPS for the fiscal year that ended in Dec. 2024 is calculated as

Basic EPS (A: Dec. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-54.753	-	0)	/	513.547
	=	-0.11

Genor Biopharma Holdings's Basic EPS for the quarter that ended in Dec. 2024 is calculated as

Basic EPS (Q: Dec. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(79.448	-	0)	/	517.416
	=	0.15

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-0.11

Genor Biopharma Holdings (HKSE:06998) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Genor Biopharma Holdings EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Genor Biopharma Holdings's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Genor Biopharma Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genor Biopharma Holdings Ltd (HKSE:06998) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

67N:Germany

Address

690 Bibo Road, Room 501-02, Building 6, Pudong New District, Shanghai, CHN, 201203

Website

https://www.genorbio.com

Genor Biopharma Holdings Ltd is a commercial-ready biopharmaceutical company focusing on developing and commercializing oncology and autoimmune drugs. The company is focused on therapeutic areas with substantial unmet medical needs in oncology, autoimmune, and other chronic diseases. Its key drug candidates includes GB491 (lerociclib), a differentiated oral CDK4/6 inhibitor; GB221, a novel HER2 mAb drug candidate; geptanolimab (GB226), GB492, a STING agonist expected to exert synergistic effects in combination with GB226; GB242, an infliximab (Remicade) biosimilar; and GB223, a RANKL, and others.

Executives

Forebright New Opportunities Fund, L.p.	2101 Beneficial owner
Forbright Global Limited	2201 Interest of corporation controlled by you
Fnof Gp Limited	2201 Interest of corporation controlled by you
Deg – Deutsche Investitions- Und Entwicklungsgesellschaft Mbh	2101 Beneficial owner
Hsg Growth V Holdco Q, Ltd.	2101 Beneficial owner
Hsg Holding Limited	2201 Interest of corporation controlled by you
Snp China Enterprises Limited	2201 Interest of corporation controlled by you
Hongshan Capital Growth Fund Management I, L.p.	2201 Interest of corporation controlled by you
Shen Nan Peng	2201 Interest of corporation controlled by you
Hongshan Capital Growth Fund I, L.p.	2101 Beneficial owner
Hongshan Capital Growth Fund V, L.p.	2201 Interest of corporation controlled by you
Hsg Growth V Management, L.p.	2201 Interest of corporation controlled by you
Hongshan Capital Management I, L.p.	2201 Interest of corporation controlled by you
Hongshan Capital I, L.p.	2101 Beneficial owner
Ni Xin	2101 Beneficial owner

Genor Biopharma Holdings Headlines

No Headlines